Meet Proteona at the “LifeTime meets industry” conference in Basel, Switzerland
Innovative AI-driven genomic and proteomic analysis platform for improving cell therapy and immuno-oncology
Meet Proteona at the “LifeTime meets industry” conference, taking place on the 31st of October in Basel, Switzerland. The LifeTime Initiative aims to understand the underlying mechanisms of key diseases on a cellular and molecular level, so that doctors will be able to improve patient diagnosis and provide personalized treatment. It is built on key technologies including single cell analysis, artificial intelligence, and patient-derived organoids models.
Take the opportunity to meet with leading researchers and industry partners. Talk to us to find out how Proteona can contribute the LifeTime vision by applying single cell proteogenomics to solve clinical questions.
For media queries, please contact:
Dr Andreas Schmidt
Proteona is a precision medicine company in Singapore, Germany, and the US that is pioneering the use of single cell multi-omics to improve clinical outcomes in cancer. Using a combination of innovative single cell assays and AI-assisted bioinformatics, Proteona enables pharmaceutical companies, biotech partners, and clinicians to integrate single cell level precision into their clinical projects. Proteona continues to develop comprehensive, disease-specific single cell databases combining gene expression, protein expression, and mutation information derived from each individual cells as well as drug response data for each sample. Proteona has been selected as a “One to Watch” by Nature Research Spinoff Award and a Winner of Falling Walls Ventures Breakthrough of the Year 2020. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research (A*STAR).